Abstract 5553
Background
High inflammatory cytokine levels can lead to severe fatigue and alter the quality of life (QoL) of family caregivers (FCGs) of patients with head and neck cancer in palliative care (HNCPC). In addition, single nucleotide variants (SNVs) in cytokine genes, such as IL1B c-598T>C (rs16944), IL1R2 c.-2009G>A (rs4141134), IL6 c.-237G>C (rs1800795), and TREML2 c.430A>G (rs3747742), can influence individual differences in cytokine production. However, the roles of the referred SNVs on the QoL of FCGs are unknown. Thus, the aim of our study was to evaluate the influence of the referred SNVs in the QoL of FCGs of patients with HNCPC.
Methods
Genomic DNA of 100 FCGs of patients with HNCPC was analyzed by real-time PCR to identify the genotypes. QoL was measured with the abbreviated World Health Organization QoL questionnaire (WHOQOL-bref). The cut-off of the score was lower than 60 for worse QoL. Differences between groups were assessed by Fisher’s exact test, chi-square (bivariate analysis), and multiple linear regression.
Results
FCGs who carried IL6 GG (62.8% vs. 49.2%, odds ratio [OR]: 2.78, 95% confidence interval [CI]: 1.03-7.44, p = 0.04) and TREML2 AA (60.0% vs. 44.6%, OR: 2.68, 95% CI: 1.03-7.01, p = 0.04) had worse QoL for the overall QoL domain than non-carriers. The frequency of the genotype TREML2 AA was higher in FCGs with lower score for physical domain (61.0% vs. 42.4%, OR: 2.69, 95% CI: 1.05-6.87, p = 0.03). FCGs who carried IL1B TT genotype had worse QoL for the social domain than others (48.9% vs. 32.1%, OR: 3.49, 95% CI: 1.03-7.01, p = 0.01).
Conclusions
Genotypes of the IL1B, IL6, and TREML genes, associated with higher inflammatory levels, seem to influence the QoL of FCGs. We believe that our results can contribute to identify FCGs with worse QoL for physical, psychological, and social aspects and provide better and more specialized care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3020 - Circulating tumor DNA (ctDNA) analysis depicts mechanisms of resistance and tumor response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
Presenter: Sandra Ortiz - Cuaran
Session: Poster Display session 1
Resources:
Abstract
1271 - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC).
Presenter: Ryo Itotani
Session: Poster Display session 1
Resources:
Abstract
1132 - Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Presenter: Aaron Cohen
Session: Poster Display session 1
Resources:
Abstract
1502 - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK Study
Presenter: David Gandara
Session: Poster Display session 1
Resources:
Abstract
3912 - Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA
Presenter: Wei Fang Hsu
Session: Poster Display session 1
Resources:
Abstract
3856 - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: a study on circulating tumor DNA
Presenter: Romano Danesi
Session: Poster Display session 1
Resources:
Abstract
1330 - Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer
Presenter: Xiaoxia Chen
Session: Poster Display session 1
Resources:
Abstract
3512 - Carcinoembryonic Antigen of Cerebrospinal Fluid Predict Prognosis of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Presenter: Junjie Zhen
Session: Poster Display session 1
Resources:
Abstract
3852 - Liquid biopsy in clinical pratice of Non-Small-Cell-Lung Cancer (NSCLC): a multi-institutional experience
Presenter: Giovanna De Maglio
Session: Poster Display session 1
Resources:
Abstract
1205 - A Phase III Study Comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC
Presenter: Martin Reck
Session: Poster Display session 1
Resources:
Abstract